The study and its comparison
Ninety people with peripheral artery disease were randomized to nicotinamide riboside, riboside plus resveratrol, or placebo for six months. The principal comparison assessed six-minute walking distance. [1][2]
The riboside-only group improved by seven meters while placebo declined by about eleven meters. The reported between-group difference was 17.6 meters with a one-sided ninety-percent confidence interval. Adding resveratrol did not improve on riboside alone. [1][2]
What the finding establishes
That statistical interval is not interchangeable with a conventional two-sided ninety-five-percent interval. Adherence-subgroup results are also less secure than randomized comparisons. An author disclosed industry research support; the record lists American Heart Association grants. A publisher correction restored the trial registration sentence, without changing the reported result. Larger confirmation is needed before broad claims about NAD supplements. [1][2]
A hypothetical distinction
Imagine two studies use different confidence levels. Their nominal significance cannot be compared without checking those choices.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product. - Publisher Correction: Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.